On November 30, 2023 Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of drug response in the tumor microenvironment (TME), reported to have entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company (Press release, Presage Biosciences, NOV 30, 2023, View Source [SID1234638076]). According to the agreement, Presage’s platform will be used by AstraZeneca in translational analysis to evaluate several investigational bispecific antibody combinations in samples taken from head and neck cancer patients. The work will contribute to advancing AstraZeneca’s growing portfolio of immuno-oncology agents looking to harness the immune system against cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Rich Klinghoffer, PhD, Chief Executive Officer of Presage, said: "Prior studies have demonstrated that the CIVO platform provides accurate guidance about the therapeutic potential of novel agents in the only context that matters: Fully intact patient tumors. We are very pleased to be working with an innovator like AstraZeneca and supporting their quest to discover, develop, and deliver transformative medicines to patients."
Earlier this month, Presage presented results from a completed Phase 0 study evaluating Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) alone and in combination with other immune-oncology agents at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023 Annual Meeting. The study enrolled patients across six US-based cancer centers in both soft tissue sarcoma and head and neck cancer. Study data highlight the importance of evaluating novel therapies in patient tumors and revealed a contradiction between results from in-vivo animal studies versus results in the intact TME.
"For too long, we have put our trust in laboratory models of cancer that do not capture the complexity of the intact TME," said Klinghoffer. "The CIVO technology was developed to address this fundamental issue in cancer drug development and the results from this study demonstrate the true power of our platform – the ability to know, early in development, how a drug impacts patient tumors."
KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.